The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started with a couple of interesting bolt-ons, and the typical incremental updates from across the industry. As always, our Evaluate Vantage team has brought together the highlights, along with context, […]
Share:
The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started with a couple of interesting bolt-ons, and the typical incremental updates from across the industry.
As always, our Evaluate Vantage team has brought together the highlights, along with context, views and what it really means for biopharma and investors alike. Check it out now.
By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.
